Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.

Shortening Buruli ulcer treatment with combination therapy targeting the respiratory chain and exploiting M. ulcerans gene decay.

Converse PJ, Almeida DV, Tyagi S, Xu J, Nuermberger EL.

Antimicrob Agents Chemother. 2019 Apr 29. pii: AAC.00426-19. doi: 10.1128/AAC.00426-19. [Epub ahead of print]

PMID:
31036687
2.

Advancing the therapeutic potential of indoleamides for tuberculosis.

Lun S, Tasneen R, Chaira T, Stec J, Onajole OK, Yang TJ, Cooper CB, Mdluli K, Converse PJ, Nuermberger EL, Raj VS, Kozikowski A, Bishai WR.

Antimicrob Agents Chemother. 2019 Apr 22. pii: AAC.00343-19. doi: 10.1128/AAC.00343-19. [Epub ahead of print]

3.

Understanding the Significance of Biochemistry in the Storage, Handling, Purification, and Sampling of Amphiphilic Mycolactone.

Kubicek-Sutherland JZ, Vu DM, Anderson AS, Sanchez TC, Converse PJ, Martí-Arbona R, Nuermberger EL, Swanson BI, Mukundan H.

Toxins (Basel). 2019 Apr 4;11(4). pii: E202. doi: 10.3390/toxins11040202.

4.

Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis.

Xu J, Li SY, Almeida DV, Tasneen R, Barnes-Boyle K, Converse PJ, Upton AM, Mdluli K, Fotouhi N, Nuermberger EL.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e00021-19. doi: 10.1128/AAC.00021-19. Print 2019 May.

5.

Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer.

Almeida DV, Omansen TF, Li SY, Lee J, Grosset JH, Converse PJ, Nuermberger EL.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e02171-18. doi: 10.1128/AAC.02171-18. Print 2019 Mar.

PMID:
30559131
6.

High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease.

Omansen TF, Almeida D, Converse PJ, Li SY, Lee J, Stienstra Y, van der Werf T, Grosset JH, Nuermberger EL.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01478-18. doi: 10.1128/AAC.01478-18. Print 2019 Feb.

PMID:
30455239
7.

Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer.

Converse PJ, Almeida DV, Tasneen R, Saini V, Tyagi S, Ammerman NC, Li SY, Anders NM, Rudek MA, Grosset JH, Nuermberger EL.

PLoS Negl Trop Dis. 2018 Aug 13;12(8):e0006728. doi: 10.1371/journal.pntd.0006728. eCollection 2018 Aug.

8.

A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis.

Leung-Theung-Long S, Coupet CA, Gouanvic M, Schmitt D, Ray A, Hoffmann C, Schultz H, Tyagi S, Soni H, Converse PJ, Arias L, Kleinpeter P, Sansas B, Mdluli K, Vilaplana C, Cardona PJ, Nuermberger E, Marchand JB, Silvestre N, Inchauspé G.

PLoS One. 2018 May 2;13(5):e0196815. doi: 10.1371/journal.pone.0196815. eCollection 2018.

9.

Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis.

Park SW, Tasneen R, Converse PJ, Nuermberger EL.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01502-17. doi: 10.1128/AAC.01502-17. Print 2017 Nov.

10.

Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis.

Li SY, Tasneen R, Tyagi S, Soni H, Converse PJ, Mdluli K, Nuermberger EL.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00913-17. doi: 10.1128/AAC.00913-17. Print 2017 Sep.

11.

Mouse model of pulmonary cavitary tuberculosis and expression of matrix metalloproteinase-9.

Ordonez AA, Tasneen R, Pokkali S, Xu Z, Converse PJ, Klunk MH, Mollura DJ, Nuermberger EL, Jain SK.

Dis Model Mech. 2016 Jul 1;9(7):779-88. doi: 10.1242/dmm.025643. Epub 2016 May 26.

12.

Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis.

Tasneen R, Betoudji F, Tyagi S, Li SY, Williams K, Converse PJ, Dartois V, Yang T, Mendel CM, Mdluli KE, Nuermberger EL.

Antimicrob Agents Chemother. 2015 Oct 26;60(1):270-7. doi: 10.1128/AAC.01691-15. Print 2016 Jan.

13.

Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease.

Converse PJ, Tyagi S, Xing Y, Li SY, Kishi Y, Adamson J, Nuermberger EL, Grosset JH.

PLoS Negl Trop Dis. 2015 Jun 4;9(6):e0003823. doi: 10.1371/journal.pntd.0003823. eCollection 2015.

14.

Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models.

Li SY, Irwin SM, Converse PJ, Mdluli KE, Lenaerts AJ, Nuermberger EL.

Antimicrob Agents Chemother. 2015 Jul;59(7):4026-30. doi: 10.1128/AAC.00105-15. Epub 2015 Apr 27.

15.

Characterization of mouse models of Mycobacterium avium complex infection and evaluation of drug combinations.

Andréjak C, Almeida DV, Tyagi S, Converse PJ, Ammerman NC, Grosset JH.

Antimicrob Agents Chemother. 2015 Apr;59(4):2129-35. doi: 10.1128/AAC.04841-14. Epub 2015 Jan 26.

16.

Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis.

Tyagi S, Ammerman NC, Li SY, Adamson J, Converse PJ, Swanson RV, Almeida DV, Grosset JH.

Proc Natl Acad Sci U S A. 2015 Jan 20;112(3):869-74. doi: 10.1073/pnas.1416951112. Epub 2015 Jan 5.

17.

Accelerated detection of mycolactone production and response to antibiotic treatment in a mouse model of Mycobacterium ulcerans disease.

Converse PJ, Xing Y, Kim KH, Tyagi S, Li SY, Almeida DV, Nuermberger EL, Grosset JH, Kishi Y.

PLoS Negl Trop Dis. 2014 Jan 2;8(1):e2618. doi: 10.1371/journal.pntd.0002618. eCollection 2014.

18.

Rapid, serial, non-invasive assessment of drug efficacy in mice with autoluminescent Mycobacterium ulcerans infection.

Zhang T, Li SY, Converse PJ, Grosset JH, Nuermberger EL.

PLoS Negl Trop Dis. 2013 Dec 19;7(12):e2598. doi: 10.1371/journal.pntd.0002598. eCollection 2013.

19.

Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice.

Grosset JH, Tyagi S, Almeida DV, Converse PJ, Li SY, Ammerman NC, Bishai WR, Enarson D, Trébucq A.

Am J Respir Crit Care Med. 2013 Sep 1;188(5):608-12. doi: 10.1164/rccm.201304-0753OC.

20.

Microbiological, histological, immunological, and toxin response to antibiotic treatment in the mouse model of Mycobacterium ulcerans disease.

Sarfo FS, Converse PJ, Almeida DV, Zhang J, Robinson C, Wansbrough-Jones M, Grosset JH.

PLoS Negl Trop Dis. 2013;7(3):e2101. doi: 10.1371/journal.pntd.0002101. Epub 2013 Mar 14.

Supplemental Content

Loading ...
Support Center